Evaluation of the protective immunity of a novel subunit fusion vaccine in a murine model of systemic MRSA infection

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Zuo, Qian Fei ^a   Yang, Liu Yang ^a   Feng, Qiang ^a   Lu, Dong Shui ^a   Dong, Yan Dong ^a   Cai, Chang Zhi ^a   Wu, Yi ^a   Guo, Ying ^a   Gu, Jiang ^a   Zeng, Hao ^a   Zou, Quan Ming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; CHIMERIC BIVALENT STAPHYLOCOCCUS VACCINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 5; IRON SURFACE DETERMINANT B; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; IMMUNE RESPONSE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; MURINAE; NONHUMAN; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; CHEMOKINES; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN G; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; OPSONIN PROTEINS; PHAGOCYTOSIS; RECOMBINANT FUSION PROTEINS; SPLEEN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 84891875397     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081212     Document Type: Article

References (35)

1. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298: 1763-1771.
2. Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, et al. (2005) Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293: 3012-3021.
3. Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339: 520-532.
4. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, et al. (2001) Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 32 Suppl 2: S114-132.
5. Durai R, Ng PC, Hoque H (2010) Methicillin-resistant Staphylococcus aureus: an update. AORN J 91: 599-606;quiz 7-9.
6. Hiramatsu K (2001) Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1: 147-155.
7. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, et al. (2003) Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302: 1569-1571.
8. Foster TJ (2005) Immune evasion by staphylococci. Nat Rev Microbiol 3: 948-58.
9. DeDent A, Kim HK, Missiakas D, Schneewind O (2012) Exploring Staphylococcus aureus pathways to disease for vaccine development. Semin Immunopathol 34: 317-333.
10. Fattom A, Schneerson R, Szu SC, Vann WF, Shiloach J, et al. (1990) Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 58: 2367-2374.
11. Fattom AI, Sarwar J, Ortiz A, Naso R (1996) A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 64: 1659-65.
12. Lee JC, Park JS, Shepherd SE, Carey V, Fattom A (1997) Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 65: 4146-51.
13. Maira-Litran T, Kropec A, Goldmann DA, Pier GB (2005) Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)- glucosamine. Infect Immun 73: 6752-6762.
14. Clarke SR, Brummell KJ, Horsburgh MJ, McDowell PW, Mohamad SAS, et al. (2006) Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis: 1098-1108.
15. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, et al. (2006) A novel Staphylococcus aureus vaccine: Iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S-aureus sepsis model. Infect Immun 74: 2215-2223.
16. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T (2001) Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184: 1572-1580.
17. Narita K, Hu DL, Mori F, Wakabayashi K, Iwakura Y (2010) Role of Interleukin-17A in Cell-Mediated Protection against Staphylococcus aureus Infection in Mice Immunized with the Fibrinogen-Binding Domain of Clumping Factor A. Infect Immun 78: 4234-4242.
18. Schaffer AC, Solinga RM, Cocchiaro J, Portoles M, Kiser KB, et al. (2006) Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 74: 2145-2153.
19. Stranger-Jones YK, Bae T, Schneewind O (2006) Vaccine assembly from surface proteins of Staphylococcus aureus. Proceedings of the National Academy of Sciences of the United States of America 103:16942-16947.
20. Nilsson IM, Patti JM, Bremell T, Hook M, Tarkowski A (1998) Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Invest 101: 2640-2649.
21. Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC (2008) Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis (4):571-575.
22. Mamo W, Jonsson P, Flock JI, Lindberg M, Muller HP, et al. (1994) Vaccination against Staphylococcus aureus mastitis: immunological response of mice vaccinated with fibronectin-binding protein (FnBP-A) to challenge with S. aureus. Vaccine 12: 988-992.
23. Schlievert PM, Shands KN, Dan BB, Schmid GP, Nishimura RD (1981) Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis 143: 509-516.
24. Valeva A, Weisser A, Walker B, Kehoe M, Bayley H, et al. (1996) Molecular architecture of a toxin pore: a 15-residue sequence lines the transmembrane channel of staphylococcal alpha-toxin. The EMBO journal 15: 1857-1864.
25. Bubeck Wardenburg J, Schneewind O (2008) Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205: 287-294.
26. Proctor RA (2012) Is there a future for a Staphylococcus aureus vaccine? Vaccine 30: 2921-2927.
27. Verkaik NJ, van Wamel WJ, van Belkum A (2011) Immunotherapeutic approaches against Staphylococcus aureus. Immunotherapy 3:1063-1073.
28. Kaslow DC, Shiver JW (2011) Clostridium difficile and Methicillin-Resistant Staphylococcus aureus: Emerging Concepts in Vaccine Development. In Annual Review of Medicin 62: 201-215.
29. Spellberg B, Daum R (2012) Development of a vaccine against Staphylococcus aureus. Semin Immunopathol 34: 335-348.
30. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, et al. (2009) Th1-Th17 Cells Mediate Protective Adaptive Immunity against Staphylococcus aureus and Candida albicans Infection in Mice. Plos Pathogens 5: e1000703.
31. Mazmanian SK, Ton-That H, Su K, Schneewind O (2002) An iron-regulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis. Proceedings of the National Academy of Sciences of the United States of America 99: 2293-2298.
32. Ebert T, Smith S, Pancari G, Clark D, Hampton R, et al. (2010) A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Human Antibodies 19: 113-128.
33. Liang XD, Ji YD (2006) Alpha-toxin interferes with integrin-mediated adhesion and internalization of Staphylococcus aureus by epithelial cells. Cellular Microbiology 8: 1656-1668.
34. Zhao YX, Nilsson IM, Tarkowski A (1998) The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis. Immunology 93: 80-85.
35. Joshi A, Pancari G, Cope L, Bowman E, Cua D, et al. (2012) Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccin Immunother 8: 336-346.